e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort
Olaf Holz, Benjamin Waschki, Henrik Watz, Anne Kirsten, Mustafa Abdo, Frauke Pedersen, Markus Weckmann, Oliver Fuchs, Anna-Maria Dittrich, Gesine Hansen, Matthias V. Kopp, Erika von Mutius, Klaus F. Rabe, Jens M. Hohlfeld, Thomas Bahmer
Source:
Eur Respir J, 57 (2) 2002127; 10.1183/13993003.02127-2020
Journal Issue:
February
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Olaf Holz, Benjamin Waschki, Henrik Watz, Anne Kirsten, Mustafa Abdo, Frauke Pedersen, Markus Weckmann, Oliver Fuchs, Anna-Maria Dittrich, Gesine Hansen, Matthias V. Kopp, Erika von Mutius, Klaus F. Rabe, Jens M. Hohlfeld, Thomas Bahmer. Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort. Eur Respir J, 57 (2) 2002127; 10.1183/13993003.02127-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Breath volatile organic compound (VOC) patterns in adult asthma patients of the ALLIANCE cohort
Source: International Congress 2019 – Evaluation of basic science in airway diseases
Year: 2019
Volatile organic compounds in COPD: Is hexanal an inflammation biomarker?
Source: International Congress 2016 – The future of lung function is beginning now
Year: 2016
Volatile organic compounds (VOCs) in COPD patients with exacerbation
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
Breath volatile organic compound (VOC) COPD study at two DZL centers - Evaluation of site-specific VOC
Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease
Year: 2015
Presence of volatile organic compounds (VOC) in exhaled breath in patients diagnosed with lung cancer (LC) vs healthy patients. Preliminary data
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
Exhaled volatile organic compounds predict exacerbations of childhood asthma in a 1-year prospective study
Source: Eur Respir J 2013; 42: 98-106
Year: 2013
Integrating monitoring of volatile organic compounds (VOCs) in asthma and COPD into the routine lung function
Source: International Congress 2015 – The next generation of lung function tests
Year: 2015
Multiple detectable exhaled volatile organic compounds (vocs) may serve as potential inflammatory biomarkers in COPD
Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment
Year: 2009
Identification of exhaled volatile organic compounds (VOCs) associated with loss of asthma control
Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Year: 2016
Volatile organic compounds in exhaled breath are associated with exacerbations in children with asthma
Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma
Year: 2009
Volatile organic compounds (VOC) in exhaled breath of patients with COPD
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in chronic and acute airway diseases
Year: 2010
Exhaled volatile organic compounds differentiate between children with atopic asthma and healthy controls
Source: Annual Congress 2009 - Paediatric lung function, imaging and methodology in health and disease
Year: 2009
Can exhaled volatile organic compounds predict asthma exacerbations in children?
Source: International Congress 2015 – Phenotyping asthma with biomarkers
Year: 2015
Volatile organic compounds in exhaled breath of patients with COPD ± lung cancer and their correlation with FEV1-values
Source: International Congress 2014 – The assessment of comorbidities
Year: 2014
Limited clinical value of exhaled volatile organic compound measurements in childhood asthma
Source: ERJ Open Res, 4 (4) 00026-2018; 10.1183/23120541.00026-2018
Year: 2018
Semi-volatile organic compounds in exhaled breath condensate: a new approach in the differential diagnosis of asthma and COPD
Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches
Year: 2009
Exhaled endogenous particles in a general population sample enriched with asthma subjects
Source: International Congress 2015 – Exhaled biomarkers in children and adults with airways disease
Year: 2015
Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD
Source: Eur Respir J 2011; 38: 1301-1309
Year: 2011
Exhaled volatile organic compounds as markers for medication use in asthma
Source: Eur Respir J, 55 (2) 1900544; 10.1183/13993003.00544-2019
Year: 2020
Analysis of semi-volatile organic compounds in exhaled breath condensate of patients with obstructive lung diseases
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept